COL18A1 and fatty liver disease: These changes suggest a combined signature of enhanced extracellular matrix remodeling (COL18A1), lipid transport dysregulation (AFM), and impaired complement-mediated immunity (C4A), highlighting potential molecular pathways linked to severe hepatic steatosis.